Metabolic and Central Nervous System Characterisation of the Phenotype of Non-suppressed (Rising) Glucagon After Glucose Challenge
Overview
- Phase
- Not Applicable
- Intervention
- Intravenous glucagon
- Conditions
- Metabolic Syndrome
- Sponsor
- University Hospital Tuebingen
- Enrollment
- 32
- Locations
- 1
- Primary Endpoint
- Brain activity
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The investigators previously characterized a phenotype with non-suppressed glucagon at 120 minutes after standardized oral glucose load. This phenotype is associated with healthy metabolic traits such as lower BMI, higher insulin sensitivity and lower liver fat content. Glucagon is a pleiotropic hormone that, besides its main action on increasing endogenous glucose production, also reduces appetite and increases basal energy expenditure. The aims of this study are to i. detect functional differences in the appetite-related central nervous system (CNS) areas between the suppressed and non-suppressed glucagon phenotype ii. mimick the non-suppressed glucagon phenotype in those participants who suppress glucagon by administering a very-low-dose glucagon infusion and retest them.
Investigators
Eligibility Criteria
Inclusion Criteria
- •BMI 18.5- 29.9 kg/m2
- •written informed consent
Exclusion Criteria
- •febrile infection with temperatures\> 38.5 ° C in the last 14 days
- •Blood donation within the last 12 weeks Pre-study Inclusion
- •Chronic diseases:
- •Diabetes mellitus
- •Known liver diseases (hepatitisB/C, hemochromatosis, NASH)
- •Chronic inflammatory diseases (rheumatoid arthritis, Crohn's disease, ulcerative colitis) chronic renal insufficiency
- •Cancer (known malignant disease)
- •psychiatric diagnoses (bipolar disorder, schizophrenia, psychoses, depression, agoraphobia)
- •Persons with non-removable metal parts, e.g:
- •pacemaker
Arms & Interventions
Intravenous glucagon
Low-dose glucagon infusion (0.5 pmol/min/kg body weight) over 150 minutes during a standardized 75 g oral glucose tolerance test
Intervention: Intravenous glucagon
Intravenous saline
Saline infusion over 150 minutes during a standardized 75 g oral glucose tolerance test
Intervention: Intravenous saline
Outcomes
Primary Outcomes
Brain activity
Time Frame: change from baseline to 120 minutes after oral glucose challenge
Resting-state brain activity assessed by fMRI
Secondary Outcomes
- Basal energy expenditure(150 minutes after oral glucose challenge)
- Hunger rating(before and 150 minutes after oral glucose challenge and start of glucagon/saline infusion)
- Glucose tolerance(0-120 minutes)
- Insulin sensitivity(0-120 minutes)
- Change in hormone levels(0-150 minutes)
- Brain response to food cues(before, 30 minutes and 120 minutes after oral glucose challenge and start of glucagon/saline infusion)